Literature DB >> 31092896

Molecular heterogeneity in peripheral T-cell lymphoma, not otherwise specified revealed by comprehensive genetic profiling.

Yasuharu Sato1,2, Hiroaki Miyoshi3, Kana Sakamoto4, Yosaku Watatani5, Kenji Nishida1, Yuka Gion2, Yasunobu Nagata5, Yuichi Shiraishi6, Kenichi Chiba6, Hiroko Tanaka6, Lanying Zhao5, Yotaro Ochi5, Yasuhide Takeuchi5, June Takeda5, Hiroo Ueno5, Yasunori Kogure5,7, Yusuke Shiozawa5, Nobuyuki Kakiuchi5, Tetsuichi Yoshizato5, Masahiro M Nakagawa5, Yasuhito Nanya5, Kenichi Yoshida5, Hideki Makishima5, Masashi Sanada8, Mamiko Sakata-Yanagimoto9, Shigeru Chiba9, Ryota Matsuoka10, Masayuki Noguchi10, Nobuhiro Hiramoto11, Takayuki Ishikawa11, Junichi Kitagawa12, Nobuhiko Nakamura12, Hisashi Tsurumi12, Tatsuhiko Miyazaki13, Yusuke Kito14, Satoru Miyano6, Kazuya Shimoda15, Kengo Takeuchi4,16, Koichi Ohshima3, Tadashi Yoshino1, Seishi Ogawa17, Keisuke Kataoka18,19.   

Abstract

Peripheral T-cell lymphoma, not otherwise specified (PTCL, NOS) is a diagnosis of exclusion, being the most common entity in mature T-cell neoplasms, and its molecular pathogenesis remains significantly understudied. Here, combining whole-exome and targeted-capture sequencing, gene-expression profiling, and immunohistochemical analysis of tumor samples from 133 cases, we have delineated the entire landscape of somatic alterations, and discovered frequently affected driver pathways in PTCL, NOS, with and without a T-follicular helper (TFH) cell phenotype. In addition to previously reported mutational targets, we identified a number of novel recurrently altered genes, such as KMT2C, SETD1B, YTHDF2, and PDCD1. We integrated these genetic drivers using hierarchical clustering and identified a previously undescribed molecular subtype characterized by TP53 and/or CDKN2A mutations and deletions in non-TFH PTCL, NOS. This subtype exhibited different prognosis and unique genetic features associated with extensive chromosomal instability, which preferentially affected molecules involved in immune escape and transcriptional regulation, such as HLA-A/B and IKZF2. Taken together, our findings provide novel insights into the molecular pathogenesis of PTCL, NOS by highlighting their genetic heterogeneity. These results should help to devise a novel molecular classification of PTCLs and to exploit a new therapeutic strategy for this group of aggressive malignancies.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31092896     DOI: 10.1038/s41375-019-0473-1

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  45 in total

1.  TET2 and DNMT3A mutations in human T-cell lymphoma.

Authors:  Lucile Couronné; Christian Bastard; Olivier A Bernard
Journal:  N Engl J Med       Date:  2012-01-05       Impact factor: 91.245

Review 2.  Peripheral T-cell lymphoma.

Authors:  Francine M Foss; Pier Luigi Zinzani; Julie M Vose; Randy D Gascoyne; Steven T Rosen; Kensei Tobinai
Journal:  Blood       Date:  2011-04-14       Impact factor: 22.113

Review 3.  Peripheral T-cell lymphoma, not otherwise specified.

Authors:  Alessandro Broccoli; Pier Luigi Zinzani
Journal:  Blood       Date:  2017-01-23       Impact factor: 22.113

4.  Recurrent TET2 mutations in peripheral T-cell lymphomas correlate with TFH-like features and adverse clinical parameters.

Authors:  François Lemonnier; Lucile Couronné; Marie Parrens; Jean-Philippe Jaïs; Marion Travert; Laurence Lamant; Olivier Tournillac; Therese Rousset; Bettina Fabiani; Rob A Cairns; Tak Mak; Christian Bastard; Olivier A Bernard; Laurence de Leval; Philippe Gaulard
Journal:  Blood       Date:  2012-07-03       Impact factor: 22.113

5.  RHOA G17V Induces T Follicular Helper Cell Specification and Promotes Lymphomagenesis.

Authors:  Jose R Cortes; Alberto Ambesi-Impiombato; Lucile Couronné; S Aidan Quinn; Christine S Kim; Ana C da Silva Almeida; Zachary West; Laura Belver; Marta Sanchez Martin; Laurianne Scourzic; Govind Bhagat; Olivier A Bernard; Adolfo A Ferrando; Teresa Palomero
Journal:  Cancer Cell       Date:  2018-02-02       Impact factor: 31.743

6.  The gene expression profile of nodal peripheral T-cell lymphoma demonstrates a molecular link between angioimmunoblastic T-cell lymphoma (AITL) and follicular helper T (TFH) cells.

Authors:  Laurence de Leval; David S Rickman; Caroline Thielen; Aurélien de Reynies; Yen-Lin Huang; Georges Delsol; Laurence Lamant; Karen Leroy; Josette Brière; Thierry Molina; Françoise Berger; Christian Gisselbrecht; Luc Xerri; Philippe Gaulard
Journal:  Blood       Date:  2007-02-06       Impact factor: 22.113

7.  Activating mutations in genes related to TCR signaling in angioimmunoblastic and other follicular helper T-cell-derived lymphomas.

Authors:  David Vallois; Maria Pamela D Dobay; Ryan D Morin; François Lemonnier; Edoardo Missiaglia; Mélanie Juilland; Justyna Iwaszkiewicz; Virginie Fataccioli; Bettina Bisig; Annalisa Roberti; Jasleen Grewal; Julie Bruneau; Bettina Fabiani; Antoine Martin; Christophe Bonnet; Olivier Michielin; Jean-Philippe Jais; Martin Figeac; Olivier A Bernard; Mauro Delorenzi; Corinne Haioun; Olivier Tournilhac; Margot Thome; Randy D Gascoyne; Philippe Gaulard; Laurence de Leval
Journal:  Blood       Date:  2016-07-01       Impact factor: 22.113

8.  Somatic RHOA mutation in angioimmunoblastic T cell lymphoma.

Authors:  Mamiko Sakata-Yanagimoto; Terukazu Enami; Kenichi Yoshida; Yuichi Shiraishi; Ryohei Ishii; Yasuyuki Miyake; Hideharu Muto; Naoko Tsuyama; Aiko Sato-Otsubo; Yusuke Okuno; Seiji Sakata; Yuhei Kamada; Rie Nakamoto-Matsubara; Nguyen Bich Tran; Koji Izutsu; Yusuke Sato; Yasunori Ohta; Junichi Furuta; Seiichi Shimizu; Takuya Komeno; Yuji Sato; Takayoshi Ito; Masayuki Noguchi; Emiko Noguchi; Masashi Sanada; Kenichi Chiba; Hiroko Tanaka; Kazumi Suzukawa; Toru Nanmoku; Yuichi Hasegawa; Osamu Nureki; Satoru Miyano; Naoya Nakamura; Kengo Takeuchi; Seishi Ogawa; Shigeru Chiba
Journal:  Nat Genet       Date:  2014-01-12       Impact factor: 41.307

9.  Recurrent mutations in epigenetic regulators, RHOA and FYN kinase in peripheral T cell lymphomas.

Authors:  Teresa Palomero; Lucile Couronné; Hossein Khiabanian; Mi-Yeon Kim; Alberto Ambesi-Impiombato; Arianne Perez-Garcia; Zachary Carpenter; Francesco Abate; Maddalena Allegretta; J Erika Haydu; Xiaoyu Jiang; Izidore S Lossos; Concha Nicolas; Milagros Balbin; Christian Bastard; Govind Bhagat; Miguel A Piris; Elias Campo; Olivier A Bernard; Raul Rabadan; Adolfo A Ferrando
Journal:  Nat Genet       Date:  2014-01-12       Impact factor: 41.307

10.  Targeted mutational profiling of peripheral T-cell lymphoma not otherwise specified highlights new mechanisms in a heterogeneous pathogenesis.

Authors:  J H Schatz; S M Horwitz; J Teruya-Feldstein; M A Lunning; A Viale; K Huberman; N D Socci; N Lailler; A Heguy; I Dolgalev; J C Migliacci; M Pirun; M L Palomba; D M Weinstock; H-G Wendel
Journal:  Leukemia       Date:  2014-09-03       Impact factor: 11.528

View more
  56 in total

1.  Gene alterations in epigenetic modifiers and JAK-STAT signaling are frequent in breast implant-associated ALCL.

Authors:  Camille Laurent; Alina Nicolae; Cécile Laurent; Fabien Le Bras; Corinne Haioun; Virginie Fataccioli; Nadia Amara; José Adélaïde; Arnaud Guille; Jean-Marc Schiano; Bruno Tesson; Alexandra Traverse-Glehen; Marie-Pierre Chenard; Lénaïg Mescam; Anne Moreau; Catherine Chassagne-Clement; Joan Somja; Frédéric Escudié; Marc André; Nadine Martin; Laetitia Lacroix; François Lemonnier; Anne-Sophie Hamy; Fabien Reyal; Marie Bannier; Lucie Oberic; Nais Prade; François-Xavier Frénois; Asma Beldi-Ferchiou; Marie-Helene Delfau-Larue; Reda Bouabdallah; Daniel Birnbaum; Pierre Brousset; Luc Xerri; Philippe Gaulard
Journal:  Blood       Date:  2020-01-30       Impact factor: 22.113

Review 2.  Peripheral T cell lymphomas: from the bench to the clinic.

Authors:  Danilo Fiore; Luca Vincenzo Cappelli; Alessandro Broccoli; Pier Luigi Zinzani; Wing C Chan; Giorgio Inghirami
Journal:  Nat Rev Cancer       Date:  2020-04-06       Impact factor: 60.716

3.  Multiple mutations at exon 2 of RHOA detected in plasma from patients with peripheral T-cell lymphoma.

Authors:  Barbara Ottolini; Nadia Nawaz; Christopher S Trethewey; Sami Mamand; Rebecca L Allchin; Richard Dillon; Paul A Fields; Matthew J Ahearne; Simon D Wagner
Journal:  Blood Adv       Date:  2020-06-09

4.  Application of NanoString technologies in angioimmunoblastic T cell lymphoma.

Authors:  Wonseok Shin; Seyoung Mun; Seungkyu Choi; Kyudong Han
Journal:  Genes Genomics       Date:  2020-03-07       Impact factor: 1.839

Review 5.  Enhancing antitumor immunity through checkpoint blockade as a therapeutic strategy in T-cell lymphomas.

Authors:  Alexander Neuwelt; Taha Al-Juhaishi; Eduardo Davila; Bradley Haverkos
Journal:  Blood Adv       Date:  2020-09-08

6.  Combined landscape of single-nucleotide variants and copy number alterations in clonal hematopoiesis.

Authors:  Ryunosuke Saiki; Yukihide Momozawa; Yasuhito Nannya; Masahiro M Nakagawa; Yotaro Ochi; Tetsuichi Yoshizato; Chikashi Terao; Yutaka Kuroda; Yuichi Shiraishi; Kenichi Chiba; Hiroko Tanaka; Atsushi Niida; Seiya Imoto; Koichi Matsuda; Takayuki Morisaki; Yoshinori Murakami; Yoichiro Kamatani; Shuichi Matsuda; Michiaki Kubo; Satoru Miyano; Hideki Makishima; Seishi Ogawa
Journal:  Nat Med       Date:  2021-07-08       Impact factor: 53.440

7.  Expression of the checkpoint receptors LAG-3, TIM-3 and VISTA in peripheral T cell lymphomas.

Authors:  Carlos A Murga-Zamalloa; Noah A Brown; Ryan A Wilcox
Journal:  J Clin Pathol       Date:  2019-10-31       Impact factor: 3.411

Review 8.  The interplay between DNA and histone methylation: molecular mechanisms and disease implications.

Authors:  Yinglu Li; Xiao Chen; Chao Lu
Journal:  EMBO Rep       Date:  2021-04-12       Impact factor: 8.807

9.  Molecularly targeted therapies for relapsed and refractory peripheral T-cell lymphomas.

Authors:  Zachary D Epstein-Peterson; Steven M Horwitz
Journal:  Semin Hematol       Date:  2021-03-03       Impact factor: 3.851

Review 10.  Biology and Molecular Pathogenesis of Mature T-Cell Lymphomas.

Authors:  José R Cortés; Teresa Palomero
Journal:  Cold Spring Harb Perspect Med       Date:  2021-05-03       Impact factor: 6.915

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.